LAMIVUDINE by Cipla is [see microbiology ( )]. Approved for chronic hepatitis b virus (hbv) infection associated with evidence of hepatitis b viral replication, active liver inflammation [see clinical studies (, active liver inflammation. First approved in 2017.
Drug data last refreshed 4h ago
[see Microbiology ( )].
The Effectiveness of Ritonavir Plus Zidovudine Plus Lamivudine in HIV-Infected Patients
Effect of Vaccination on Turnover of Lamivudine (3TC) Sensitive and Resistant Virus Populations in HIV-1-Infected Individuals
Comparison of Telbivudine Versus Lamivudine on the Early Dynamics and Kinetics of Viral Suppression in Chronic Hepatitis B
A Study to Compare the Safety and Effectiveness of Indinavir Combined With Stavudine and Lamivudine
Safety and Effectiveness of Giving Indinavir Plus Stavudine Plus Lamivudine to HIV-Infected Children
Worked on LAMIVUDINE at Cipla? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.